Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

52486-19-8

52486-19-8 structure

Name: 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-pyrimidine-2,4-dione
Chemical Name: 1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
CAS Number: 52486-19-8
Molecular Formula: C₁₀H₁₄N₂O₆
Molecular Weight: 258.23
Catalog: Signaling Pathways Cell Cycle/DNA Damage Nucleoside Antimetabolite/Analog
Create Date: 2017-06-18 01:39:49
Modify Date: 2026-07-12 13:18:29
1-(β-D-Xylofuranosyl)-5-methyluracil is a thymidine analog. Analogs of this series have insertional activity towards replicated DNA. They can be used to label cells and track DNA synthesis[1].

Name	1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
Synonyms	1-(-D-Xylofuranosyl)-5-methyluracil 1-(beta-D-Xylofuranosyl)-5-methyluracil 9-(bbeta-D-Xylofuranosyl)-5-methyluracil, xylo-5-methyl uridine 5-Methyl-1-β-D-xylofuranosyl-2,4(1H,3H)-pyrimidinedione Xylo-5-methyluridine 9-(b-D-Xylofuranosyl)-5-methyluracil, xylo-5-methyl uridine 1-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione 1-(b-D-Xylofuranosyl)-5-methyluracil 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-β-D-xylofuranosyl

Description	1-(β-D-Xylofuranosyl)-5-methyluracil is a thymidine analog. Analogs of this series have insertional activity towards replicated DNA. They can be used to label cells and track DNA synthesis[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> Nucleoside Antimetabolite/Analog
References	[1]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. [2]. Cavanagh BL, et al. Thymidine analogues for tracking DNA synthesis. Molecules. 2011 Sep 15;16(9):7980-93.